Cyclacel Pharmaceuticals Inc (CYCC)
2.29
+0.18
(+8.53%)
USD |
NASDAQ |
May 08, 12:09
Cyclacel Pharmaceuticals Enterprise Value: -0.5964M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | -0.5964M |
| May 06, 2024 | -0.6491M |
| May 03, 2024 | -0.7414M |
| May 02, 2024 | -0.0954M |
| May 01, 2024 | 0.1155M |
| April 30, 2024 | -0.5832M |
| April 29, 2024 | -1.585M |
| April 26, 2024 | -1.387M |
| April 25, 2024 | -1.269M |
| April 24, 2024 | -0.346M |
| April 23, 2024 | -1.018M |
| April 22, 2024 | -1.071M |
| April 19, 2024 | -1.031M |
| April 18, 2024 | -0.9391M |
| April 17, 2024 | -0.7941M |
| April 16, 2024 | -1.176M |
| April 15, 2024 | -1.308M |
| April 12, 2024 | -1.058M |
| April 11, 2024 | -0.8205M |
| April 10, 2024 | -0.6755M |
| April 09, 2024 | -0.5964M |
| April 08, 2024 | -0.5964M |
| April 05, 2024 | -0.6096M |
| April 04, 2024 | -0.4874M |
| April 03, 2024 | -0.4909M |
| Date | Value |
|---|---|
| April 02, 2024 | -0.5832M |
| April 01, 2024 | -0.6755M |
| March 28, 2024 | -0.5965M |
| March 27, 2024 | -0.7941M |
| March 26, 2024 | -0.8469M |
| March 25, 2024 | -0.5568M |
| March 22, 2024 | -0.4936M |
| March 21, 2024 | -0.5041M |
| March 20, 2024 | -0.412M |
| March 19, 2024 | -0.28M |
| March 18, 2024 | -0.0691M |
| March 15, 2024 | -0.1745M |
| March 14, 2024 | -0.0877M |
| March 13, 2024 | 0.0364M |
| March 12, 2024 | -0.1074M |
| March 11, 2024 | -0.0559M |
| March 08, 2024 | 0.1023M |
| March 07, 2024 | -0.0954M |
| March 06, 2024 | -0.2536M |
| March 05, 2024 | 0.0364M |
| March 04, 2024 | 0.1814M |
| March 01, 2024 | 0.4451M |
| February 29, 2024 | -0.0032M |
| February 28, 2024 | 0.155M |
| February 27, 2024 | 0.2078M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-18.55M
Minimum
Jun 13 2022
43.63M
Maximum
Mar 19 2021
-1.293M
Average
-3.255M
Median
Dec 20 2023
Enterprise Value Benchmarks
| Corvus Pharmaceuticals Inc | 56.71M |
| Oragenics Inc | 4.426M |
| Relmada Therapeutics Inc | 18.94M |
| Alpine Immune Sciences Inc | 3.912B |
| MAIA Biotechnology Inc | 62.00M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.271M |
| Revenue (Quarterly) | 0.031M |
| Total Expenses (Quarterly) | 5.391M |
| EPS Diluted (Quarterly) | -6.23 |
| Profit Margin (Quarterly) | -17.00K% |
| Earnings Yield | -1.18K% |
| Normalized Earnings Yield | -1163.88 |